Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E

被引:30
作者
Ostapchuk, P [1 ]
Hearing, P [1 ]
机构
[1] SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA
关键词
D O I
10.1128/JVI.75.1.45-51.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Adenoviruses (Ad) show promise as a vector system for gene delivery in vivo. However, a major challenge in the development of Ad vectors is the circumvention of the host immune responses to Ad infection, including both the host cytotoxic T-cell response and the humoral response resulting in neutralizing antibodies. One method to circumvent the effect of neutralizing antibodies against an Ad vector is to use different Ad serotypes to deliver the transgene of interest. This approach has been demonstrated with Ad genomes of highly related members of subgroup C, However, it is not known whether an Ad5-based vector DNA molecule can be packaged into capsids of evolutionarily more divergent adenoviruses, The aim of these studies was to determine if capsids containing hexon proteins from other Ad subgroups could package the Ad5 genome. A genetic approach utilizing an Ad5 temperature-sensitive (ts) mutant with a mutation in the hexon protein was used. When groan at the nonpermissive temperature, Ad5 ts147 replicates normally, providing a source of Ad5 DNA for virus assembly, but does not produce virus particles due to the hexon protein mutation, Coinfection of Ad5 ts147 with a wild-type virus of other Ad serotypes (Ad3, Ad4, or Ad9), which supply functional hexon proteins, resulted in the pseudopackaging of the Ad5 DNA genome. Furthermore, the pseudopackaged Ad5 DNA virions obtained in the coinfections were infectious. Therefore, switching herons did not impair the infectivity or uncoating process of the pseudopackaged virion. Since hexon protein is a major antigenic determinant of the Ad capsid, this approach may prove useful to reduce the antigenicity of therapeutic Ad vectors and allow repeated vector administration.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 48 条
[21]   Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung [J].
Kaplan, JM ;
Smith, AE .
HUMAN GENE THERAPY, 1997, 8 (09) :1095-1104
[22]  
Kaplan JM, 1996, GENE THER, V3, P117
[23]  
KassEisler A, 1996, GENE THER, V3, P154
[24]   CHARACTERIZATION OF A TEMPERATURE-SENSITIVE, HEXON TRANSPORT MUTANT OF TYPE-5 ADENOVIRUS [J].
KAUFFMAN, RS ;
GINSBERG, HS .
JOURNAL OF VIROLOGY, 1976, 19 (02) :643-658
[25]   LONG-TERM HEPATIC ADENOVIRUS-MEDIATED GENE-EXPRESSION IN MICE FOLLOWING CTLA4LG ADMINISTRATION [J].
KAY, MA ;
HOLTERMAN, AX ;
MEUSE, L ;
GOWN, A ;
OCHS, HD ;
LINSLEY, PS ;
WILSON, CB .
NATURE GENETICS, 1995, 11 (02) :191-197
[26]   High-capacity adenoviral vectors for gene transfer and somatic gene therapy [J].
Kochanek, S .
HUMAN GENE THERAPY, 1999, 10 (15) :2451-2459
[27]  
Lochmuller H, 1996, GENE THER, V3, P706
[28]   Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype [J].
Mack, CA ;
Song, WR ;
Carpenter, H ;
Wickham, TJ ;
Kovesdi, I ;
Harvey, BG ;
Magovern, CJ ;
Isom, OW ;
Rosengart, T ;
FalckPedersen, E ;
Hackett, NR ;
Crystal, RG ;
Mastrangeli, A .
HUMAN GENE THERAPY, 1997, 8 (01) :99-109
[29]   ''Sero-switch'' adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype [J].
Mastrangeli, A ;
Harvey, BG ;
Yao, J ;
Wolff, G ;
Kovesdi, I ;
Crystal, RG ;
FalckPedersen, E .
HUMAN GENE THERAPY, 1996, 7 (01) :79-87
[30]   ADENOVIRUS PROTEIN-PROTEIN INTERACTIONS - HEXON AND PROTEIN-VI [J].
MATTHEWS, DA ;
RUSSELL, WC .
JOURNAL OF GENERAL VIROLOGY, 1994, 75 :3365-3374